Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.

Abstract: A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6. with the proviso that at least one but not more than two of X1, X2, X3 and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X5 is a group selected from N or CR7 and X6 is a group selected from O, S or NR8; X7 and X8 which may be the same or different is a group selected from N or CR9; X9 is a group selected from O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and selected from a group N or CR11; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.

Abstract: The present invention includes compound of formula (I), or a derivative thereof, wherein Y is CH or N; R1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclcyl and the alkyl moieties may each inedepently be unsubstituted or substituted; and R2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention inlcudes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.

Abstract: The present invention includes compound of formula (I), or a derivative thereof wherein Y is CH or N; R1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclcyl and the alkyl moieties may each inedepently be unsubstituted or substituted; and R2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention inlcudes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.

Abstract: The present invention includes compound of formula (I), or a derivative thereof, wherein Y is CH or N; R1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclyl and the alkyl moieties may each independently be unsubstituted or substituted; and R2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention includes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.

Abstract: A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6. with the proviso that at least one but not more than two of X1, X2, X3 and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X5 is a group selected from N or CR7 and X6 is a group selected from O, S or NR8; X7 and X8 which may be the same or different is a group selected from N or CR9; X9 is a group selected from O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and selected from a group N or CR11; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.

Abstract: A method of treating an Msk-1 and/or ROCK(1 and 2) mediated disease or condition in a mammal comprising administration of an effective amount of a compounds of the formula (I) and physiologically acceptable salts thereof wherein, R1 is a 5, or 6 membered heterocyclic group selected from group a, b, c or d wherein X1 is a group selected from N or CR7 and X2 is a group selected from O, S or NR8; X3 and X4 which may be the same or different is a group selected from N or CR7; X5 is a group selected from O, S or NR8 and X6 is N or CR7; X7, X8 and X9 may be the same or different and selected from a group N or CR7, pharmaceutical compositions, novel compounds and processes for their preparation.

Abstract: A connector housing having a contact secured therein is provided. The connector housing includes inner walls that define a contact-receiving chamber. The contact-receiving chamber includes a channel along at least a portion of one of the inner walls for receiving a contact retention member. The contact-receiving chamber may include multiple channels for receiving multiple contact retention members. The contact includes a body section having the contact retention member thereon. The contact may include multiple body sections. The contact retention member includes a bulge portion flared outward in a direction transverse to the body section. The contact retention member may include multiple bulge portions and the multiple bulge portions may flare outward and inward in opposite directions from one another. When the contact is loaded into the housing and the contact retention member is received by the channel, the bulge portion frictionally engages at least one of the inner walls of the contact-receiving chamber.

Abstract: A multi-beam power contact is provided including a main body and a plurality of at least three beams, which may be grouped in beam pairs, extending from the main body. The beams are adapted for mating with a mating connector, and the beams comprise contact areas adapted for electrical connection with the mating connector. Additionally, the multi-beam power contact may optionally include at least one initial contact beam and at least one non-initial contact beam. The initial contact beam is arranged to electrically connect to the mating connector before the non-initial contact beam electrically connects while the multi-beam power contact is being mated.

Abstract: The present invention includes compound of formula (I), 1

Abstract: A connector housing having a contact secured therein is provided. The connector housing includes inner walls that define a contact-receiving chamber. The contact-receiving chamber includes a channel along at least a portion of one of the inner walls for receiving a contact retention member. The contact-receiving chamber may include multiple channels for receiving multiple contact retention members. The contact includes a body section having the contact retention member thereon. The contact may include multiple body sections. The contact retention member includes a bulge portion flared outward in a direction transverse to the body section. The contact retention member may include multiple bulge portions and the multiple bulge portions may flare outward and inward in opposite directions from one another. When the contact is loaded into the housing and the contact retention member is received by the channel, the bulge portion frictionally engages at least one of the inner walls of the contact-receiving chamber.

Abstract: A multi-beam power contact is provided including a main body and a plurality of at least three beams, which may be grouped in beam pairs, extending from the main body. The beams are adapted for mating with a mating connector, and the beams comprise contact areas adapted for electrical connection with the mating connector. Additionally, the multi-beam power contact may optionally include at least one initial contact beam and at least one non-initial contact beam. The initial contact beam is arranged to electrically connect to the mating connector before the non-initial contact beam electrically connects while the multi-beam power contact is being mated.